Loading...
•
Dec 31, 2023
Ironwood Pharmaceuticals Q4 2023 Earnings Report
Reported fourth quarter and full year 2023 results, achieving 2023 financial guidance.
Key Takeaways
Ironwood Pharmaceuticals reported its fourth quarter and full year 2023 results. LINZESS U.S. net sales reached $1.1 billion, a 7% increase year-over-year, driven by EUTRx prescription demand growth of 10% year-over-year. Ironwood's revenue was $443 million, primarily driven by $430 million in U.S. LINZESS collaboration revenue.
LINZESS prescription demand increased a robust 10% year-over-year.
LINZESS received FDA approval for functional constipation in pediatric patients ages 6 to 17.
Strengthened GI pipeline with the addition of apraglutide.
Expect topline results from the STARS Phase III study of apraglutide in March of 2024.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Revenue by Segment
Revenue by Segment
LINZESS Collaboration Revenue
CapyFin.com Forward Guidance
Ironwood remains focused on maximizing LINZESS, advancing GI pipeline and delivering sustained profits and cash flows.
Positive Outlook
- Continued strong LINZESS performance.
- Key pipeline catalysts ahead.
- Topline data from STARS Phase 3 study expected in March.
- Topline data from ongoing Phase 2 study for CNP-104 expected in the third quarter.
- Believe it can propel Ironwood’s next phase of growth and create value for patients and shareholders in the years to come.